Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer

European Journal of Cancer

Volumn 41, Issue 17, 2005, Pages 2760-2768

  Kotzsch, Matthias ^a   Farthmann, Juliane ^b   Meye, Axel ^a   Fuessel, Susanne ^a   Baretton, Gustavo ^a   Tjan Heijnen, Vivianne C G ^c   Schmitt, Manfred ^b   Luther, Thomas ^a,d   Sweep, Fred C G J ^c   Magdolen, Viktor ^b   Span, Paul N ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Medical Laboratory Unit   (Germany)

Author keywords

Breast cancer; Prognosis; Quantitative real time PCR; Tissue inhibitor of metalloproteinase 3; Urokinase receptor transcript variants

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RECURRENT CANCER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 27744522730     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.09.002     Document Type: Article

References (34)

1. P.Z. Khasigov, O.V. Podobed, and T.S. Gracheva Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis Biochemistry (Mosc) 68 2003 711 717
2. N. Sidenius, and F. Blasi The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy Cancer Metastasis Rev 22 2003 205 222
3. C.A. Borgono, and E.P. Diamandis The emerging roles of human tissue kallikreins in cancer Nat Rev Cancer 4 2004 876 890
4. M.A. Engelse, R. Hanemaaijer, and P. Koolwijk The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression Semin Thromb Hemost 30 2004 71 82
5. C. Jedeszko, and B.F. Sloane Cysteine cathepsins in human cancer Biol Chem 385 2004 1017 1027
6. A. Nœl, C. Maillard, and N. Rocks Membrane associated proteases and their inhibitors in tumour angiogenesis J Clin Pathol 57 2004 577 584
7. M.J. Duffy The urokinase plasminogen activator system: role in malignancy Curr Pharm Des 10 2004 39 49
8. M.K. Durand, J.S. Bodker, and A. Christensen Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis Thromb Haemost 91 2004 438 449
9. J. Rømer, B.S. Nielsen, and M. Ploug The urokinase receptor as a potential target in cancer therapy Curr Pharm Des 10 2004 2359 2376
10. S. Sperl, M.M. Mueller, and O.G. Wilhelm The uPA/uPA receptor system as a target for tumor therapy Drug News Perspect 14 2001 401 411
11. S. Stefansson, G.A. McMahon, and E. Petitclerc Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling Curr Pharm Des 9 2003 1545 1564
12. N. Harbeck, R.E. Kates, and K. Gauger Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer Thromb Haemost 91 2004 450 456
13. C.E. de Bock, and Y. Wang Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer Med Res Rev 24 2004 13 39
14. U. Reuning, V. Magdolen, and S. Hapke Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins Biol Chem 384 2003 1119 1131
15. M.C. Kugler, Y. Wei, and H.A. Chapman Urokinase receptor and integrin interactions Curr Pharm Des 9 2003 1565 1574
16. T. Luther, M. Kotzsch, and A. Meye Tumor-associated urokinase receptor splice variants Thromb Haemost 89 2003 705 717
17. J.W. Martens, A.M. Sieuwerts, and J. Bolt-deVries Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression Thromb Haemost 89 2003 393 404
18. J. Farthmann, L. Holzscheiter, and J. Biermann Development of quantitative RT-PCR assays for wild-type urokinase receptor (uPAR-wt) and its splice variant uPAR-del5 Radiol Oncol 38 2004 111 119
19. U. Magdolen, J. Krol, and S. Sato Natural inhibitors of tumor-associated proteases Radiol Oncol 36 2002 131 143
20. D.R. Edwards TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges J Pathol 202 2004 391 394
21. P.N. Span, R.L.P. Lindberg, and P. Manders Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success J Pathol 202 2004 395 402
22. M. Schmitt, O.G. Wilhelm, and U. Reuning The urokinase plasminogen activator system as a novel target for tumour therapy Fibrinol Proteol 14 2000 114 132
23. J.A. Foekens, H.A. Peters, and M.P. Look The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients Cancer Res 60 2000 636 643
24. C. Bouchet, K. Hacene, and P.M. Martin Dissemination risk index based on plasminogen activator system components in primary breast cancer J Clin Oncol 17 1999 3048 3057
25. M. Kotzsch, T. Luther, and N. Harbeck New ELISA for quantitation of human urokinase receptor (CD87) in cancer Int J Oncol 17 2000 827 834
26. N. Montuori, V. Visconte, and G. Rossi Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules Thromb Haemost 93 2005 192 198
27. J.R. Casey, J.G. Petranka, and J. Kottra The structure of the urokinase-type plasminogen activator receptor gene Blood 84 1994 1151 1156
28. C. Pyke, J. Eriksen, and H. Solberg An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator FEBS Lett 326 1993 69 74
29. D.G. Altman, B. Lausen, and W. Sauerbrei Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829 835
30. A. Mondino, and F. Blasi uPA and uPAR in fibrinolysis, immunity and pathology Trends Immunol 25 2004 450 455
31. L.J. van 't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
32. Y. Wang, J.G. Klijn, and Y. Zhang Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 2005 671 679
33. S. Michiels, S. Koscielny, and C. Hill Prediction of cancer outcome with microarrays: a multiple random validation strategy Lancet 365 2005 488 492
34. X.J. Ma, Z. Wang, and P.D. Ryan A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616